Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

29 trials with published results (14%)

Research Maturity

107 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.6%

16 terminated out of 210 trials

Success Rate

87.0%

+0.5% vs benchmark

Late-Stage Pipeline

11%

23 trials in Phase 3/4

Results Transparency

27%

29 of 107 completed with results

Key Signals

29 with results87% success16 terminated

Data Visualizations

Phase Distribution

156Total
Not Applicable (67)
Early P 1 (5)
P 1 (38)
P 2 (23)
P 3 (10)
P 4 (13)

Trial Status

Completed107
Unknown52
Recruiting24
Terminated16
Not Yet Recruiting4
Withdrawn4

Trial Success Rate

87.0%

Benchmark: 86.5%

Based on 107 completed trials

Clinical Trials (210)

Showing 20 of 20 trials
NCT05313165Not ApplicableRecruitingPrimary

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

NCT07383064Not ApplicableCompletedPrimary

Single Versus Multiple Vessels Endovascular Tibial Arteries Revascularization for Critical Limb Ischemia

NCT03807661Not ApplicableCompletedPrimary

Percutaneous Deep Vein Arterialization Post-Market Study

NCT06122974Not ApplicableNot Yet RecruitingPrimary

Drug Eluting Temporary Spur Stent System vs Percutaneous Balloon Angioplasty for the Treatment of Critical Limb Ischemia

NCT03321552Not ApplicableCompletedPrimary

PROMISE International

NCT03529019Early Phase 1RecruitingPrimary

Nutrition in Patient With Critical Limb Ischemia

NCT05145478Recruiting

CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

NCT00696124Phase 1CompletedPrimary

Safety Study of Gene Therapy in Treating Critical Leg Ischemia

NCT01064440Phase 2CompletedPrimary

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

NCT05854615Phase 4RecruitingPrimary

Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease

NCT05854641Phase 4RecruitingPrimary

Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease

NCT05358353Not ApplicableCompleted

A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)

NCT05009602Completed

Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes

NCT04433572Phase 3Recruiting

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

NCT02051088Not ApplicableActive Not Recruiting

Swedish Drug-elution Trial in Peripheral Arterial Disease

NCT07093632Completed

Medium-term Results of Lower Limb Arterial Bypass

NCT02807779Phase 4Completed

Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging

NCT02963649Not ApplicableCompletedPrimary

IN.PACT BTK Randomized Study to Assess Safety and Efficacy of IN.PACT 014 vs. PTA

NCT04191746CompletedPrimary

BEST vCLI Registry

NCT06434194Not ApplicableRecruitingPrimary

Serrantor OCT Study

Scroll to load more

Research Network

Activity Timeline